Plasmid DNA Manufacturing Market Revenue to Attain USD 12.45 Bn by 2035

Plasmid DNA Manufacturing Market Revenue and Trends 2026 to 2035

The global plasmid DNA manufacturing market revenue accounted at USD 2.64 billion in 2025 and is predicted to increase from USD 3.20 billion in 2026 to approximately USD 12.45 billion by 2035, expanding at a CAGR of 16.78% from 2026 to 2035. The market is observed to grow rapidly due to the propelling demand for growth in the biopharmaceutical industry and higher demand for generic options of branded drugs and doses. 

Market at a Glance

The plasmid DNA manufacturing market involves the production, purification, and supply of circular DNA molecules, highly used in gene therapies, mRNA vaccines, and cell-based treatments. The market also covers services for designing, developing, and manufacturing high-quality pDNA, ranging from pre-clinical to large-scale commercial production. The procedure also involves fermentation, separation, and purification. 

• Growth of mRNA Vaccine- The growing adoption of mRNA vaccines post-pandemic for vaccines is one of the major factors for the growth of the market. The technology is ideal for curing infectious diseases. 
  Moderna, the company known for Spikewax and a robust pipeline targeting influenza, RSV, and personalized cancer vaccines. 
• Technological Advancements- Technological advancements are one of the major factors for the growth of the market in the foreseen period. It helps the industry in advanced purification, automation, and upstream processing efficiency, which is helpful to increase yields and lower production costs. 
  Aldevron, a well-known name, is highly popular for advanced production of custom pDNA, protein, and antibodies to utilize single-use systems to optimize turnaround times. 

Market Forecast

• CDMO Partnerships and Outsourcing- One of the major opportunities fueling the growth of the plasmid DNA manufacturing market involves outsourcing various complex manufacturing procedures to CDMOs, which helps to create significant demand for high-quality pDNA production. 
  AGC Biologics- The company is a key plasmid DNA CDMO provider offering end-to-end services, including customized, GMP-compliant pDNA production for viral vectors and gene therapy. 
• Scalable Manufacturing Technologies- Another major opportunity for the growth of the market involves scalable fermentation and purification technologies. The technologies are highly aimed at addressing bottlenecks in commercial-scale production. 
  Wacker Biotech US- The company offers a scalable, customized platform process for GMP plasmid production with high-density fermentation capacity. 
• Integration of AI in Production Procedure- Use of AI for yield prediction, process optimization, and reducing failure rate is one of the major factors helpful for the growth of the market. 
  Catalent Inc.- The company utilizes its platform for AI-supported process analytical technology to streamline manufacturing, reduce development time, and achieve higher yields. 

Secondary Data

The table above reflects the estimated percentage value of various diseases contributing to the growth of the plasmid DNA manufacturing market. The table clearly shows that cancer has a major dominance over the market with a share of approximately 41%. Increasing development of DNA-based cancer vaccines and CAR-T cell therapies relying heavily on high-quality plasmid vectors is also a major market driver. Another major sector dominating the market’s growth involves infectious diseases, reflecting a share of approximately 33%. The segment’s growth is propelled by the ongoing demand for DNA vaccines and viral vector production. Genetic disorders and other medical issues also aid the growth of the market. 

Market Segmentation Overview

• By product type, the viral vector segment dominated the global plasmid DNA manufacturing market in 2025. The major shift of the market towards CDMOs for capacity, with Adeno-Associated Virus and lentiviral vectors leading in application. 
• By product type, the non-viral vectors segment is observed to be the fastest-growing segment with the highest CAGR in the foreseen period. The segment’s growth is majorly driven by lower immunogenicity, easier manufacturing scalability, and stability with development in lipid nanoparticles for delivery. 
• By application, the gene therapy segment dominated the global market with a share of approximately 59% in 2025. Growing demand for high-quality pDNA as a raw material for viral vectors and direct gene-based medicines is a major factor propelling the growth of the market. 
• By application, the DNA vaccines segment is observed to be the fastest-growing segment in the foreseen period with the highest CAGR. Higher demand for DNA/mRNA vaccines and gene therapies is one of the major factors helping the growth of the market. 
• By disease, the infectious disease segment had a major dominance over the global market in 2025, driven by higher usage of DNA plasmid in the treatment of various infectious diseases to improve immunity through vaccine antigens and prevent pathogen infections. 
• By disease, the cancer segment is observed to have the highest CAGR in the foreseen period due to the growing use of vectors for the development of cancer treatment therapies. 

Regional Analysis

North America led the global plasmid DNA manufacturing market in 2025. Higher disposable income, presence of major industry players in the region, improved healthcare infrastructure, and consumer awareness regarding gene therapies are some of the major factors that help fuel the growth of the market. Higher concentration of pharmaceutical companies and CDMOs in the region is one of the major factors helping to propel the market’s growth in the foreseeable period. Major investments in the market by its well-known players are another major factor propelling the market’s growth. 

Asia Pacific is observed to be the fastest-growing region in the foreseen period with the highest CAGR. Factors such as increased government investment in the healthcare sector for its improved infrastructure and services are one of the major market drivers. Major investments by the well-known names of the market to facilitate research and development activities in the field of plasmid DNA are another major factor propelling the market’s growth. China has made a major contribution to the market’s growth, driven by increasing clinical trials for cell and gene therapies. 

Top Companies of Plasmid DNA Manufacturing Market 

• Aldevron- The company serves as a critical supplier for cell and gene therapies, mRNA vaccines, and gene editing. The company is also known for its customized production of plasmid DNA, mRNA, and recombinant proteins. 
• Plasmidfactory GmBH- The company is a leading contract manufacturer, leading in high-quality plasmid and minicircle DNA production for R&D, gene therapy, and virus production. 
• Vigene Biosciences- The company provides CDMO services for plasmid DNA, viral vectors, and related services as well. 
• Luminous Biosciences- The company provides customized, high-quality plasmid design and production services for early-stage R&D, preclinical studies, and therapeutic development. 
• Akron Biotech- The well-known name of the industry provides specialized GMP-compliant raw materials and CDMO for cell and gene therapies. The company also focuses on manufacturing high-quality clinical-grade plasmid DNA to support advancements in vaccines and regenerative medicines. 

Segments Covered in the Report

By Product

• Viral Vectors
• Plasmid DNA
• Non-Viral
• Electroporation
• Lipid/Polymer
• Nanoparticles
• Others

By Application

• Gene Therapy
• DNA Vaccines
• Immunotherapy
• Others

By Disease

• Infectious Disease
• Genetic Disorder
• Cancer

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @https://www.precedenceresearch.com/sample/1299

You can place an order or ask any questions, please feel free to contact us at [email protected] |+1 804 441 9344